Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function

Thrombosis Research

Volumn 123, Issue 2, 2008, Pages 374-380

  Adams, M J ^a,b   Irish, A B ^c   Watts, G F ^d   Oostryck, R ^b   Dogra, G K ^c,d  

^a UNIVERSITY OF TASMANIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Blood coagulation; Chronic kidney disease; Endothelium; Thrombin generation; Tissue factor

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7C; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 6; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING; CELL FUNCTION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIUM; FEMALE; HUMAN; HYPERCOAGULABILITY; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; UPREGULATION;

AGED; ANTIGENS; ANTITHROMBIN III; BIOLOGICAL MARKERS; BIOLOGICAL PROCESSES; BLOOD COAGULATION; CREATININE; E-SELECTIN; ENDOTHELIUM, VASCULAR; FACTOR VII; FACTOR X; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN S; PROTHROMBIN; RENAL DIALYSIS; SOLUBILITY; THROMBOMODULIN; THROMBOPHILIA; THROMBOPLASTIN;

EID: 55549133259     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.03.024     Document Type: Article

References (39)

1. Molino D., De Lucia D., and Gaspare De Santo N. Coagulation disorders in uremia. Semin Nephrol 26 (2006) 46-51
2. Ambuhl P.M., Wuthrich R.P., Korte W., Schmid L., and Krapf R. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant 12 (1997) 2355-2364
3. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 28 (1985) 429-439
4. Charytan D.M., Kuntz R.E., Chhabra A., and Cutlip D.E. Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting. J Nephrol 19 (2006) 764-770
5. Koren-Morag N., Goldbourt U., and Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 67 (2006) 224-228
6. Stack A.G. Coronary artery disease and peripheral vascular disease in chronic kidney disease: an epidemiological perspective. Cardiol Clin 23 (2005) 285-298
7. McVey J.H. Tissue factor pathway. Baillieres Clin Haematol 7 (1994) 469-484
8. Takagi M., Wada H., Mukai K., Kihira H., Yano S., Minamikawa K., et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coagul Fibrinolysis 5 (1994) 713-717
9. Rustom R., Leggat H., Tomura H.R., Hay C.R., and Bone J.M. Plasma thrombomodulin in renal disease: effects of renal function and proteinuria. Clin Nephrol 50 (1998) 337-341
10. Dogra G., Irish A., Chan D., and Watts G. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 48 (2006) 926-934
11. Dogra G.K., Herrmann S., Irish A.B., Thomas M.A., and Watts G.F. Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrol Dial Transplant 17 (2002) 2220-2225
12. Woodman R.J., Playford D.A., Watts G.F., Cheetham C., Reed C., Taylor R.R., et al. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol 91 (2001) 929-937
13. Adams M., Breckler L., Stevens P., Thom J., Baker R., and Oostryck R. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation. Haematologica 89 (2004) 985-990
14. Sagripanti A., Cupisti A., Baicchi U., Ferdeghini M., Morelli E., and Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 63 (1993) 273-278
15. Canavese C., Stratta P., Pacitti A., Mangiarotti G., Racca M., Oneglio R., et al. Impaired fibrinolysis in uremia: partial and variable correction by four different dialysis regimes. Clin Nephrol 17 (1982) 82-89
16. Hong S.Y., and Yang D.H. Fibrinolytic activity in end-stage renal disease. Nephron 63 (1993) 188-192
17. Gris J.C., Branger B., Vecina F., al Sabadani B., Fourcade J., and Schved J.F. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 46 (1994) 807-813
18. Escolar G., Diaz-Ricart M., and Cases A. Uremic platelet dysfunction: past and present. Curr Hematol Rep 4 (2005) 359-367
19. Remuzzi G. Bleeding in renal failure. Lancet 1 (1988) 1205-1208
20. Rabelink T.J., Zwaginga J.J., Koomans H.A., and Sixma J.J. Thrombosis and hemostasis in renal disease. Kidney Int 46 (1994) 287-296
21. Matsuo T., Koide M., Kario K., Suzuki S., and Matsuo M. Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure. Haemostasis 27 (1997) 163-167
22. Mezzano D., Tagle R., Pais E., Panes O., Perez M., Downey P., et al. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb Res 88 (1997) 465-472
23. Irish A.B., and Green F.R. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype. Nephrol Dial Transplant 13 (1998) 679-684
24. Irish A.B., and Thompson C.H. The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. Nephrol Dial Transplant 11 (1996) 2223-2228
25. Garcia-Avello A., Garcia-Frade L.J., Gandarias C., Ocana J., Cancelas J.A., and Lasso M. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA. Thromb Res 73 (1994) 109-115
26. Takahashi H., Wada K., Niwano H., and Shibata A. Comparison of prothrombin fragment 1 + 2 with thrombin-antithrombin III complex in plasma of patients with disseminated intravascular coagulation. Blood Coagul Fibrinolysis 3 (1992) 813-818
27. Faure V., Dou L., Sabatier F., Cerini C., Sampol J., Berland Y., et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost 4 (2006) 566-573
28. Al-Saady N.M., Leatham E.W., Gupta S., Kwan J.T., Eastwood J.B., and Seymour C.A. Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart 81 (1999) 134-140
29. Mercier E., Branger B., Vecina F., Al-Sabadani B., Berlan J., Dauzat M., et al. Tissue factor coagulation pathway and blood cells activation state in renal insufficiency. Hematol J 2 (2001) 18-25
30. Alwakeel J., Gader A.M., Hurieb S., al-Momen A.K., Mitwalli A., and Abu Aisha H. Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis. Int Urol Nephrol 28 (1996) 255-261
31. Tomura S., Nakamura Y., Tachibana K., Deguchi F., Ando R., Chida Y., et al. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis. Blood Purif 11 (1993) 370-377
32. Vaziri N.D., Paule P., Toohey J., Hung E., Alikhani S., Darwish R., et al. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 144 (1984) 1802-1803
33. Vaziri N.D., Gonzales E.C., Wang J., and Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 23 (1994) 828-835
34. Demicheli M., Contino L., Iberti M., Ortensia A., Finotto E., Lombardi A., et al. Protein C and protein S levels in uremic patients before and after dialysis. Thromb Res 68 (1992) 451-457
35. Lai K.N., Yin J.A., Yuen P.M., and Li P.K. Effect of hemodialysis on protein C, protein S, and antithrombin III levels. Am J Kidney Dis 17 (1991) 38-42
36. Lai K.N., Yin J.A., Yuen P.M., and Li P.K. Protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis. Nephron 56 (1990) 271-276
37. Kario K., Matsuo T., Yamada T., and Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 71 (1994) 275-279
38. Naumnik B., Borawski J., Pawlak K., and Mysliwiec M. Effect of hemodialysis on plasma levels of vascular endothelial markers. Clin Appl Thromb Hemost 8 (2002) 245-250 Official Journal Of The International Academy Of Clinical And Applied Thrombosis/Hemostasis
39. Szotowski B., Antoniak S., Poller W., Schultheiss H.P., and Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 96 (2005) 1233-1239